Literature DB >> 3515947

Localization of Chlamydia trachomatis infection by direct immunofluorescence and culture in pelvic inflammatory disease.

N B Kiviat, P Wølner-Hanssen, M Peterson, J Wasserheit, W E Stamm, D A Eschenbach, J Paavonen, J Lingenfelter, T Bell, V Zabriskie.   

Abstract

Fifty-five women with suspected pelvic inflammatory disease underwent diagnostic laparoscopy and endometrial and tubal biopsy, with specimens for isolation of Chlamydia trachomatis and for staining with a species-specific monoclonal fluorescein-conjugated antibody to C. trachomatis were obtained from the urethra, rectum, endocervix, endometrium, tubes, and cul-de-sac. C. trachomatis was isolated from 21 patients (38%), including 10 (18%) who had positive endometrial or tubal cultures. The fluorescein-conjugated antibody stain was positive for 43 (86%) of 50 culture-positive specimens, for 14 (18%) of 78 culture-negative specimens from 21 patients who had positive cultures from other sites, and for one (0.5%) of 192 specimens from 34 patients who had negative cultures at all sites. Thus the sensitivity of direct fluorescein-conjugated antibody for culture-positive specimens was 86% and the specificity for specimens from culture-negative patients was 99%. Twelve upper genital tract specimens were positive by fluorescein-conjugated antibody only. Fluorescein-conjugated antibody staining of 50 paraffin-embedded endometrial aspirates showed extracellular or intracellular elementary bodies and or cytoplasmic inclusions in all of seven culture-positive specimens, in four of six culture-negative specimens from patients who had positive cultures at other sites, and in none of 34 specimens from patients with negative cultures. Thus fluorescein-conjugated antibody staining is useful for confirming the role of C. trachomatis in endometritis and salpingitis. It is more sensitive than culture for detection of chlamydia in endometrial or tubal specimens and is able to confirm that the organism is actually present in endometrial tissue (rather than simply reflecting contamination from the cervix) in women with clinical evidence of pelvic inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515947     DOI: 10.1016/0002-9378(86)90473-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  25 in total

Review 1.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?

Authors:  I Simms; J M Stephenson
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

Review 2.  Chlamydial infections.

Authors:  J Schachter
Journal:  West J Med       Date:  1990-11

3.  Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms.

Authors:  Krupakar Jayarapu; Micah Kerr; Susan Ofner; Raymond M Johnson
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

Review 4.  Laboratory techniques for the diagnosis of chlamydial infections.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  Genitourin Med       Date:  1991-06

5.  Endocervical Chlamydia trachomatis infection in Canadian adolescents.

Authors:  E G Hughes; J Mowatt; J E Spence
Journal:  CMAJ       Date:  1989-02-01       Impact factor: 8.262

Review 6.  Pathogenesis of pelvic inflammatory disease.

Authors:  L Weström; P Wölner-Hanssen
Journal:  Genitourin Med       Date:  1993-02

7.  Consequences of incomplete antibacterial treatment for chlamydial pelvic inflammatory disease.

Authors:  M J Rosenberg; M S Waugh
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  Detection of chlamydial inclusions in cell culture or biopsy tissue by alkaline phosphatase-anti-alkaline phosphatase staining.

Authors:  J B Mahony; J Sellors; M A Chernesky
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

Review 9.  Microbiota and pelvic inflammatory disease.

Authors:  Harsha Sharma; Reshef Tal; Natalie A Clark; James H Segars
Journal:  Semin Reprod Med       Date:  2014-01-03       Impact factor: 1.303

10.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.